In a Phase 1/1b clinical trial, an oral small molecule inhibitor of A2AR (CPI-444) has shown anti-tumor activity in monotherapy and in combination with Atezolizumab in anti-PD-1/PD-L1 resistant and PDL-1-negative patients (146). The gene discussed is CD274; the disease is neoplasm.